Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 20/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 19/20 | 0.40 |
| ▸ | ITGB6 | P18564 | 7/20 | 0.38 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.37 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.37 |
| ▸ | ITGB8 | P26012 | 3/20 | 0.37 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7587378 | 1.00 | ITGAV (0.40) | ITGAVITGB3ITGB6ITGB1ITGA5 | |
| SCHEMBL6304533 | 0.81 | ITGAV (0.57) | ITGAVITGB3ITGB6ITGB1ITGA5 | |
| SCHEMBL6304539 | 0.81 | ITGAV (0.57) | ITGAVITGB3ITGB6ITGB1ITGA5 | |
| SCHEMBL20091314 | 0.79 | ITGB3 (0.46) | ITGAVITGB3ITGB6ITGB1ITGA5 | |
| SCHEMBL6433042 | 0.79 | ITGAV (0.55) | ITGAVITGB3ITGB6ITGB1ITGA5 | |
| SCHEMBL6433044 | 0.79 | ITGAV (0.55) | ITGAVITGB3ITGB6ITGB1ITGA5 | |
| SCHEMBL7591473 | 0.76 | ITGAV (0.51) | ITGAVITGB3ITGB6ITGB1ITGA5 | |
| SCHEMBL7591479 | 0.76 | ITGAV (0.51) | ITGAVITGB3ITGB6ITGB1ITGA5 | |
| SCHEMBL18105228 | 0.73 | ITGAV (0.41) | ITGAVITGB3ITGB6ITGB8ITGB5 | |
| SCHEMBL18105225 | 0.72 | ITGB3 (0.38) | ITGAVITGB3ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190307735-A1 | Composition and Methods for Treating Chronic Kidney Disease | MERCK SHARP & DOHME CORP (US) | 2019-10-10 | — | — | US | disclosed |
| US-6472403-B2 | IMIDAZOLIDIN-2-ONE DERIVATIVES; INHIBITING BONE RESORPTION, VASCULAR RESTENOSIS, DIABETIC RETINOPATHY, MACULAR DEGENERATION, ANGIOGENESIS, ATHEROSCLEROSIS, INFLAMMATION, ARTHRITIS, VIRAL DISEASE, CANCER AND METASTATIC TUMOR GROWTH | MERCK & CO., INC. | 2002-10-29 | — | — | US | disclosed |
| US-20020037889-A1 | Alpha V integrin receptor antagonists | MERCK SHARP & DOHME CORP. | 2002-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190307735-A1 | Composition and Methods for Treating Chronic Kidney Disease | ITGAM, ITGB1, ITGB2 | ITGAV 5/4885ITGB3 9/4885ITGB6 24/4885 |
| US-20020037889-A1 | Alpha V integrin receptor antagonists | ITGAV, ITGB3, ITGA5 | ITGAV 1/4885ITGB3 2/4885ITGB6 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.